NCT01992094

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages ≥18 Years of Age

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,680 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	QIVc	Novartis Investigational Quadrivalent Vaccine
BIOLOGICAL	TIV1c	Licensed Influenza Vaccine
BIOLOGICAL	TIV2c	Novartis Investigational Vaccine

Timeline

• Start date: 2013-11-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2013-11-25
• Last updated: 2015-12-10
• Results posted: 2015-12-10

Locations

40 sites across 1 country: United States